MapLight Therapeutics CDO sells 36K shares

MapLight Therapeutics, Inc. reporting person Anatol Kreitzer, Chief Discovery Officer, reported selling 36,284 shares of Voting Common Stock from July 15–17, 2026 at weighted-average prices, with underlying trade prices ranging from $35.68 to $38.21 per share.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. reporting person Anatol Kreitzer, Chief Discovery Officer, reported selling 36,284 shares of Voting Common Stock from July 15–17, 2026 at weighted-average prices, with underlying trade prices ranging from $35.68 to $38.21 per share. Sales on July 15–16 covered statutory tax withholding from vesting restricted stock units via mandated “sell to cover” transactions, while July 17 sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. Following these transactions, Kreitzer directly held 174,906 shares of Voting Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 36,284 shares

Net Sell 7 txns

Insider Kreitzer Anatol

Role Chief Discovery Officer

Sold 36,284 shs ($1.35M)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock F6, F7	2,833	$37.05	$105K
Sale	Voting Common Stock F6, F8	14,140	$37.70	$533K
Sale	Voting Common Stock F6	200	$38.39	$8K
Sale	Voting Common Stock F1, F4	7,464	$36.66	$274K
Sale	Voting Common Stock F1, F5	1,592	$37.44	$60K
Sale	Voting Common Stock F1, F2	5,545	$36.13	$200K
Sale	Voting Common Stock F1, F3	4,510	$36.94	$167K

Holdings After Transaction: Voting Common Stock — 174,906 shares (Direct)

Footnotes (8)

1. F1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025.
7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 36,284 shares Sale price range: $35.68–$38.21 per share Holdings after transactions: 174,906 shares +1 more

4 metrics

Shares sold 36,284 shares Aggregate Voting Common Stock sales reported from July 15–17, 2026

Sale price range $35.68–$38.21 per share Trade price ranges disclosed in weighted-average price footnotes F2–F5, F7–F8

Holdings after transactions 174,906 shares Direct Voting Common Stock held by Anatol Kreitzer following the latest reported sale

Largest single reported sale 14,140 shares at $37.70 per share Voting Common Stock sale dated July 17, 2026 with weighted-average price

Key Terms

Rule 10b5-1 trading plan, restricted stock units, statutory tax withholding obligations, "sell to cover" transaction

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"in connection with the vesting of the restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

statutory tax withholding obligations financial

"to cover the statutory tax withholding obligations in connection with the vesting..."

"sell to cover" transaction financial

"to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share sales did MapLight Therapeutics (MPLT) disclose for Anatol Kreitzer?

Anatol Kreitzer reported selling 36,284 shares of MapLight Therapeutics Voting Common Stock between July 15 and July 17, 2026. The trades combined tax-related “sell to cover” transactions tied to vesting RSUs and additional sales made under a Rule 10b5-1 trading plan.

How many MPLT shares does Anatol Kreitzer hold after the reported Form 4 transactions?

After the reported sales, Anatol Kreitzer directly holds 174,906 shares of MapLight Therapeutics Voting Common Stock. This figure comes from the post-transaction holding amount disclosed for the most recent transaction included in the Form 4 filing for July 2026.

Were Anatol Kreitzer’s recent MPLT share sales discretionary or tax-related?

Sales on July 15–16, 2026 were mandated “sell to cover” transactions to satisfy statutory tax withholding obligations on vesting restricted stock units, and are described as non-discretionary. Sales on July 17, 2026 were executed under a Rule 10b5-1 trading plan.

At what prices were the MPLT shares sold by Anatol Kreitzer in July 2026?

The reported per-share prices are weighted averages, such as $36.13, $36.94, $36.66, $37.44, $37.05, $37.70 and $38.39. Footnotes state that individual trades occurred within ranges from $35.68 up to $38.21 per share across the different sale transactions.

What does the Rule 10b5-1 trading plan reference mean in MPLT’s Form 4?

The Form 4 notes that certain July 17, 2026 sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. This indicates those trades followed a pre-established plan described in the footnote rather than being timed on an ad hoc basis.

Which MPLT transactions were identified as tax “sell to cover” trades for Anatol Kreitzer?

Four sales on July 15 and July 16, 2026 carry a footnote stating they represent shares required to be sold to cover statutory tax withholding obligations related to vesting restricted stock units, and that these mandated “sell to cover” sales are not discretionary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kreitzer Anatol

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Discovery Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	07/15/2026		S(1)		5,545(1)	D	$36.13(2)	205,645	D
Voting Common Stock	07/15/2026		S(1)		4,510(1)	D	$36.94(3)	201,135	D
Voting Common Stock	07/16/2026		S(1)		7,464(1)	D	$36.66(4)	193,671	D
Voting Common Stock	07/16/2026		S(1)		1,592(1)	D	$37.44(5)	192,079	D
Voting Common Stock	07/17/2026		S(6)		2,833(6)	D	$37.05(7)	189,246	D
Voting Common Stock	07/17/2026		S(6)		14,140(6)	D	$37.7(8)	175,106	D
Voting Common Stock	07/17/2026		S(6)		200(6)	D	$38.39	174,906	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)